Begins Coverage on Pulmatrix (NASDAQ:PULM)

Stock analysts at began coverage on shares of Pulmatrix (NASDAQ:PULMGet Free Report) in a note issued to investors on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Pulmatrix Stock Performance

Shares of NASDAQ:PULM opened at $1.87 on Monday. Pulmatrix has a one year low of $1.55 and a one year high of $2.88. The stock has a market cap of $6.83 million, a PE ratio of -0.78 and a beta of 0.90. The business’s fifty day moving average price is $1.91 and its two-hundred day moving average price is $1.88.

Pulmatrix (NASDAQ:PULMGet Free Report) last released its earnings results on Friday, May 10th. The biotechnology company reported $0.23 EPS for the quarter. The firm had revenue of $5.89 million during the quarter. Pulmatrix had a negative return on equity of 44.05% and a negative net margin of 75.73%.

About Pulmatrix

(Get Free Report)

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.

Featured Stories

Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with's FREE daily email newsletter.